Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

• DOI: 10.1038/s42003-021-01801-2
• Publication Date: 2021-03-01T11:07:32Z
• Authors: Romain Darrigrand; Alison Pierson; Marine Rouillon; Dolor Renko; Mathilde Boulpicante; David Bouyssié; Emmanuelle Mouton...; Julien Marcoux; Camille Garcia; Michael Ghosh; Mouad Alami; Sébastien Apcher
• Keywords: Druggability; Cancer Immunotherapy

Abstract The success of cancer immunotherapy relies on the induction an immunoprotective response targeting tumor antigens (TAs) presented MHC-I molecules. We demonstrated that splicing inhibitor isoginkgetin and its water-soluble non-toxic derivative IP2 act at production stage pioneer translation products (PTPs). showed increases PTP-derived antigen presentation in cells vitro impairs growth vivo. action is long-lasting dependent CD8 + T cell against TAs. observed repertoire displayed molecules surface MCA205 fibrosarcoma modified upon treatment with IP2. In particular, enhances exon-derived epitope from suppressor nischarin. combination a peptide vaccine nischarin-derived synergistic antitumor effect These findings identify spliceosome as druggable target for development epitope-based immunotherapies.